*Disseminated on Behalf of Medicus Pharma Ltd.
Paul Prescott Declares (MDCX) Is Back On Our Radar!
Full Coverage Starts This Morning—Thursday, December 4, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email. Take A Look At (MDCX) While It's Still Early…
December 4, 2025
Minutes Before the Bell | Here's Why (MDCX) Has My Full Focus This Morning Dear Reader, Every now and then, you spot a setup that doesn't just whisper for attention—it leans in and grabs the front of your shirt. Momentum, timing, fresh potential catalysts… all tightening at once. That's exactly what's happening right now with Medicus Pharma Ltd. (NASDAQ: MDCX).
We've covered this name before, but the latest sequence of developments has pushed it right back onto our radar heading into Thursday morning, December 4, 2025—and the timing couldn't be more interesting. Remember, (MDCX) is working with an ultra-thin float of under 8M shares according to MarketWatch. When supply sits that low, it doesn't take much for the tape to move—and we've already seen what that can look like. Just this year alone, (MDCX) has posted several sharp overnight jumps, including: - 03/11 → 03/12: $2.42 to $3.44 - approx 42% overnight move
- 08/20 → 08/21: $1.90 to $2.48 - approx 30% overnight move
- 02/13 → 02/14: $2.90 to $3.86 - approx 22% overnight move
These aren't theoretical patterns—they're actual moves recorded on the chart. Add in insider ownership north of 35%—the kind of alignment that often signals confidence behind the scenes—and you can see why momentum watchers are paying attention again. All signs point to a setup worth a closer look. Analyst Targets Suggests Over 1,400% Upside Potential
From Recent Range…
Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 1,400% upside potential from its recent $1.75 range. That's not the only target now in play. Brookline Capital's Kumaraguru Raja recently raised his target from $12 to $20, while Maxim Group's Jason McCarthy reiterated a $20 target in a report published a few days ago—reflecting continued confidence and over 1,000% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Signals Green Light for SkinJect's Streamlined Path Forward
Medicus Pharma Ltd. (NASDAQ: MDCX) has announced positive feedback from a Type C meeting with the U.S. FDA regarding its SkinJect program — a dissolvable microneedle patch designed to non-invasively treat basal cell carcinoma (BCC). The FDA agreed that the company may pursue the 505(b)(2) regulatory pathway, a streamlined route that could reduce both cost and development time by leveraging existing doxorubicin safety data. The agency also provided constructive guidance on study design, endpoints, and formulation refinements, including recommendations for an adhesive layer and applicator system to improve precision and consistency. (MDCX) is currently advancing two Phase 2 studies for its SkinJect program. In the United States, the SKNJCT-003 trial has already enrolled more than 75% of its planned 90 participants and continues to show encouraging progress following a positively trending interim analysis earlier this year. At the same time, a second Phase 2 study (SKNJCT-004) is underway across six clinical sites in the United Arab Emirates, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City. The company expects to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request an End-of-Phase 2 meeting with the FDA in Q1 2026. Medicus estimates that the market potential for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari stated that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," adding that confidence continues to grow as development progresses. (MDCX) Opens New Pathway for Patients With
Compassionate Use Partnership
Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in
Global Phase 2 Expansion
Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. (MDCX) Bolsters Clinical Portfolio With Teverelix
—A Dual-Use Phase 2b Candidate Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential.
Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. Recent Developments
Dec 01, 2025 – Appointment of Carolyn Bonner as Chief Financial Officer
Medicus promoted its President, Carolyn Bonner, to Chief Financial Officer, strengthening its executive leadership as the company scales its clinical, regulatory, and future commercial operations. Her expanded role is expected to support Medicus through its next phase of growth. Nov 24, 2025 – Company Highlights Expanded Innovation Across Skin and Prostate Cancer Programs
Medicus released an in-depth update showcasing the strategic value of both its SkinJect D-MNA platform for BCC and its late-stage Teverelix program addressing high-need prostate cancer and acute urinary retention. The company emphasized its multi-market pipeline expansion and growing clinical footprint. Nov 17, 2025 – FDA CNPV Application Filed for SkinJect (SKNJCT-003)
Medicus submitted its Commissioner's National Priority Voucher (CNPV) application for SkinJect, positioning the program for a potential 1–2 month FDA review instead of the standard 10–12 months. The application highlights SkinJect's alignment with national priorities such as affordability, access, domestic manufacturing, public-health impact, and rare-disease relevance, including Gorlin Syndrome. Nov 14, 2025 – Q3 2025 Corporate Update & Financial Highlights
Medicus reported continued progress across its SkinJect and Teverelix programs, expanded trial activity in the U.S., U.K., and UAE, and strengthened patient-access initiatives through the Gorlin Syndrome Alliance. The company also improved its balance sheet with $10.4M in new capital and reaffirmed confidence in its growing global clinical footprint. 7 Indicators Why (MDCX) Is Topping Our Watchlist This Morning
1. Tiny Float: with fewer than 8M shares available, (MDCX)'s small float has the potential for big moves if demand begins to shift. 2. Chart Moves: the chart for (MDCX) has already shown multiple overnight jumps this year — including approximate moves of 42%, 30%, and 22% — catching the attention of momentum watchers. 3. Analyst Targets: fresh coverage has placed (MDCX) as high as $27, signaling over 1,400% upside potential relative to its recent $1.75 range. 4. Insider Alignment: leadership continues to hold more than 35% of (MDCX)'s float, reinforcing long-term confidence behind the scenes. 5. Regulatory Tailwind: recent FDA Type C feedback has given (MDCX)'s SkinJect program a clearer and potentially faster 505(b)(2) route. 6. Global Progress: new clinical activity across U.S., U.K., and UAE sites shows (MDCX) expanding its SkinJect program on multiple fronts. 7. Pipeline Depth: following the Antev acquisition, (MDCX) now holds two late-stage therapeutic programs—SkinJect and Teverelix—each targeting high-need medical conditions. All seven factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Take A Look At (MDCX) While It's Still Early…
With all of these forces stacking at once, (MDCX) sits in a rare position—one shaped by a float under 8M shares, a chart that has already produced multiple sharp overnight moves, and analyst targets stretching as high as $27 from its recent $1.75 range, which suggest over 1,400% upside potential.
Add in leadership holding more than a third of the float, fresh FDA alignment on a streamlined regulatory path, expanding Phase 2 activity across three regions, and a broadened pipeline now anchored by two late-stage programs… and it becomes clear why this name refuses to drift quietly into the background. We have all eyes on (MDCX) this morning. Take a look at (MDCX) while it's still early. Also, keep a lookout for my next update, it could be here very shortly. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
| 
